Copyright
©The Author(s) 2022.
World J Clin Cases. Oct 6, 2022; 10(28): 10120-10129
Published online Oct 6, 2022. doi: 10.12998/wjcc.v10.i28.10120
Published online Oct 6, 2022. doi: 10.12998/wjcc.v10.i28.10120
Table 2 Therapeutic strategy and the laboratory examinations
| April 9, 2020 | May 30, 2020 | May 31, 2020 | June 16, 2020 | June 23, 2020 | |
| Treatment | TMP-SMZ 0.96 g q8 h + linezolid 0.6 g q12 h | TMP-SMZ 0.96 g q12 h + linezolid 0.6 g qd | TMP-SMZ 0.96 g q12 h + ceftriaxone 2 g/d | TMP-SMZ 0.96 g q12 h and minocyline 100 mg q12 h | |
| WBC (109/L) | 4.03 | 3.34 | 4.07 | 3.91 | |
| PLT (109 /L) | 379 | 130 | 219 | 185 | |
| The dose of linezolid (mg/L) | No | 9.36 | 6.38 | No | |
- Citation: Li T, Chen YX, Lin JJ, Lin WX, Zhang WZ, Dong HM, Cai SX, Meng Y. Successful treatment of disseminated nocardiosis diagnosed by metagenomic next-generation sequencing: A case report and review of literature. World J Clin Cases 2022; 10(28): 10120-10129
- URL: https://www.wjgnet.com/2307-8960/full/v10/i28/10120.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i28.10120